Beaverton teen receives highest Girl Scouts honor for STEM work
Isha Garg, a junior at Jesuit High School, was introduced to the world of STEM in elementary school, joining a prestigious club in fifth grade.
'It really opened my eyes,' she said.
Joining the club ignited a passion, and Garg wanted to share that passion with the community.
Garg currently is running a STEM club for girls in second through fifth grade in the Bethany community.
'I first didn't provide them with the book,' she said. 'Because I wanted them to experience hands-on activity.'
The Girl Scouts helped get the project off the ground — Garg has been an active member of the organization since first grade.
'Girl Scouts supported me fully. They gave me all the resources to succeed,' she said.
According to a report by the US Census Bureau in 2023, women account for only 26% of workers in STEM fields. Garg believes that can be changed by introducing girls to science earlier.
At her club, young girls get to hone their skills in coding, chemistry, biology and forensics.
While she appreciates the award, she says the real award is in the work itself.
'I really wanted to help girls as early as second grade…so they could have more opportunities, they could find something they love, and they could continue doing that in middle school through high school,' she said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Cognizant's AI Lab Records 59th U.S. Patent, Continuing to Generate AI Breakthroughs
In 2025, the Lab has yielded two new U.S. Granted Patents, open-sourced a key AI development platform, and earned a Gold Award from GECCO TEANECK, N.J., July 24, 2025 /CNW/ -- Cognizant (Nasdaq: CTSH) today announced that its AI Lab has been granted two new U.S. patents and a gold award for a research paper on "Realizing Human Expertise through AI" presented this month at GECCO (Genetic and Evolutionary Computation Conference) in Malaga, Spain. "Being granted two new U.S. patents in the first half of 2025—bringing our AI Lab's U.S. total to 59 with 23 more patents pending—underscores our relentless pace of innovation," said Babak Hodjat, CTO of AI at Cognizant. "Couple this with a Gold Award at GECCO and these milestones reflect our deep commitment to pioneering transformative AI technologies and turning cutting-edge ideas into real-world impact." The two latest patents highlight key innovations from Cognizant's AI research: U.S. Patent No. 12,282,845 (issued on April 22, 2025) covers a method for Multi-objective Coevolution of Deep Neural Network Architectures, aimed at improving model performance and resource efficiency. The method's application ranges from medical image classification to natural language processing. U.S. Patent No. 12,292,944 (issued on May 6, 2025) outlines a method for optimizing loss functions through Taylor Series Expansion, aiming to improve training efficiency and enhance model robustness, especially is data-limited scenarios.1 These innovations, developed by Cognizant's researchers including Dr. Jason Liang, Dr. Elliot Meyerson and Professor Risto Miikkulainen, reinforce Cognizant's leadership in pushing the boundaries of AI and machine learning. To make the promise of artificial intelligence both more practical and broadly accessible, earlier this year, Cognizant's AI Lab open sourced its Neuro AI Multi-Agent Accelerator. Neuro AI helps businesses accelerate their development and adoption of AI agents, transforming their business processes for adaptive operations, real-time decision-making, and personalized customer experiences tailored to client-defined objectives and oversight. The Cognizant AI Lab, which opened its San Francisco-based flagship AI research facility in March 2024, has also been honored with the Gold Award for Human-Competitive Results at GECCO 2025 for its groundbreaking work on RHEA (Realizing Human Expertise through AI). Developed by Dr. Elliott Meyerson and Professor Risto Miikkulainen RHEA employs evolutionary AI to distill and recombine hundreds of models generated by human expert teams—most notably those submitted to the XPRIZE Pandemic Response Challenge—into refined decision strategies. In a rigorous evaluation, RHEA surpassed the performance of individual human submissions, realizing the latent potential even in incompletely developed human ideas, resulting in innovative pandemic policy recommendations. This milestone underlines Cognizant's leadership in harnessing global human expertise to drive next‑generation AI solutions. Risto Miikkulainen, VP of Research and Professor of Computer Science at UT Austin, said, "RHEA is a powerful example of how evolutionary AI can amplify global human intelligence—not just by matching expert solutions, but by going beyond them to discover novel, high-impact strategies. This recognition by the Humies Award committee reinforces the promise of population-based AI as a foundation for solving the world's most complex challenges." About Cognizant Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at or @cognizant. About the Cognizant AI Lab The mission of the Cognizant AI Lab is to maximize human potential with Decision AI, a form of AI that combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create sophisticated decision-making systems. Decision AI powers Cognizant's Neuro® AI platform, which is utilized by Fortune 500 companies and non-profits to discover new ways to exceed their goals. The platform enables organizations to rapidly build AI that optimizes decision-making, leading to revenue growth and societal progress. Led by AI pioneers Babak Hodjat and Risto Miikkulainen, the lab collaborates with institutions, academia, and technology partners to develop groundbreaking AI solutions responsibly. With over 120 patents (issued or pending) globally, the lab excels at combining scientific innovation with commercial application. It supports Cognizant's goal of improving everyday life, focusing on business and AI-for-good applications. For more information, contact:Jeff DeMarrais: Paul Jarratt: Gabrielle Gugliocciello: _____________________________ 1 Descriptions of patented technologies are simplified for general understanding. For full legal scope, please refer to the issued patents linked above View original content to download multimedia: SOURCE Cognizant View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
NASA's new ‘game-changing' satellite to revolutionize Earth observation
PORTLAND, Ore. (KOIN) — NASA is about to launch a new satellite, and it isn't just an upgrade. The federal agency says the satellite is a total game-changer when it comes to collecting information about our Earth. Dubbed NISAR, the launch also marks the first joint space mission between the U.S. and India. Dr. Karen St. Germian, NASA Director of Earth Science, joined us on AM Extra to explain what this new space equipment means for planet observation. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
18-06-2025
- Business Wire
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA ® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to both scientific opportunity and patient need. 'I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,' said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. 'In recent years, we've made remarkable progress across all facets of our innovation engine, achieving numerous drug approvals and positive Phase 3 readouts, and rapidly increasing the size of our clinical pipeline. As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases.' 'As we begin this exciting new chapter, I am energized about what lies ahead for Alnylam R&D and for patients,' said Dr. Garg. 'I believe we are just beginning to scratch the surface of what RNAi therapeutics can do to improve human health. Our ambition is to deliver RNAi therapeutics to every major tissue in the body and thereby address many additional diseases that lack effective treatments. It's a privilege for me to have the opportunity to work with and lead an integrated R&D organization that has already validated a new class of medicines so that we can imagine the next generation of treatments, drive them from the lab to approval, and help patients live healthier lives.' Dr. Garg joined Alnylam in 2014 to build and lead the Company's Development group. He previously held leadership roles at Bristol-Myers Squibb and Millennium Pharmaceuticals. He received a B.A. with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco (UCSF). He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining the industry. About RNAi Therapeutics RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectation that a combined R&D organization will accelerate pipeline progress; Alnylam's ability to scale its impact and transform the lives of patients across a growing number of diseases; the potential for RNAi therapeutics to improve human health; Alnylam's ability to deliver RNAi therapeutics to every major tissue in the body and to address many additional diseases that lack effective treatments; and Alnylam's ability to imagine the next generation of treatments, achieve regulatory approval for additional treatments and to help patients live healthier lives should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its 'Alnylam P 5 x25' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
